BiotechTube

PD-L1 peptide

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

Feb 18, 2019 → Mar 10, 2021

NCT ID
NCT03850522

About PD-L1 peptide

PD-L1 peptide is a phase 2 stage product being developed by IO Biotech for Smoldering Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03850522. Target conditions include Smoldering Multiple Myeloma.

What happened to similar drugs?

0 of 1 similar drugs in Smoldering Multiple Myeloma were approved

Approved (0) Terminated (0) Active (1)
🔄Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03850522Phase 2Terminated

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
35
BHQ880NovartisPhase 2
35
carfilzomib + Lenalidomide + Dexamethasone + MelphalanAmgenPhase 2
39
DenosumabAmgenPhase 2
35
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
39
ElranatamabPfizerPhase 2
42
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
35
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
35
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
42
LinvoseltamabRegeneron PharmaceuticalsPhase 2
39
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
47
SelinexorKaryopharm TherapeuticsPhase 2
32
IPH2101Innate PharmaPhase 2
25